Advertisement

Journal of Genetic Counseling

, Volume 24, Issue 3, pp 388–399 | Cite as

Aligning Policy to Promote Cascade Genetic Screening for Prevention and Early Diagnosis of Heritable Diseases

  • Rani GeorgeEmail author
  • Karen Kovak
  • Summer L. Cox
PROFESSIONAL ISSUES

Abstract

Cascade genetic screening is a methodology for identifying and testing close blood relatives of individuals at increased risk for heritable conditions and follows a sequential process, minimizing testing costs and the number of family members who need to be tested. It offers considerable potential for cost savings and increased awareness of heritable conditions within families. CDC-classified Tier 1 genomic applications for hereditary breast and ovarian cancer syndrome (HBOC), Lynch Syndrome (LS), and familial hypercholesterolemia (FH) are recommended for clinical use and support the use of cascade genetic screening. Most individuals are unaware of their increased risk for heritable conditions such as HBOC, LS, and FH. Consistent implementation of cascade genetic screening could significantly increase awareness and prevention of heritable conditions. Limitations to effective implementation of cascade genetic screening include: insufficient genetic risk assessment and knowledge by a majority of healthcare providers without genetics credentials; a shortage of genetic specialists, especially in rural areas; a low rate of reimbursement for comprehensive genetic counseling services; and an individual focus on prevention by clinical guidelines and insurance coverage. The family-centric approach of cascade genetic screening improves prevention and early diagnosis of heritable diseases on a population health level. Cascade genetic screening could be better supported and augmented through changes in health policy.

Keywords

Cascade genetic screening Familial hypercholesterolemia Genetic counseling Healthcare reform Hereditary breast and ovarian cancer syndrome Hereditary conditions Heritable disease Lynch syndrome Policy change 

Notes

Acknowledgments

The Centers for Disease Control and Prevention (CDC) Cooperative Agreement, Division of Cancer Prevention and Control, provided funding for project activities through the Enhancing Breast Cancer Genomic Practices through Education, Surveillance, and Policy; CDC-RFA-DP11-1114; FOA DP11-114 award #5U58DP003790. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the CDC.

Conflict of Interest

The authors declare no conflicts of interest.

Animal or Human Studies

No animal or human studies were carried out by the authors for this article. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients being included in the study.

References

  1. Ambry Genetics (2014). 2014 CPT Codes and Client Pricing. Retrieved from http://www.ambrygen.com/sites/default/files/Master_Pricelist_testName_1_17_2014_0.pdf.
  2. American Board of Genetic Counseling (2013). About ABGC. Retrieved from http://www.abgc.net/ABGC/AmericanBoardofGeneticCounselors.asp.
  3. American Board of Medical Genetics and Genomics. (2013). Number of Certified Specialists in Genetics. Retrieved from http://www.abmgg.org/pages/resources_certspecial.shtml.
  4. American College of Surgeons, Commission on Cancer (2012). Cancer Program Standards 2012: Ensuring Patient-Centered Care (V 1.2.1). Retrieved from http://www.facs.org/cancer/coc/programstandards2012.pdf
  5. American Society of Human Genetics Social Issues, Subcommittee on Familial Disclosure. (1998). ASHG statement. professional disclosure of familial genetic information. American Journal of Human Genetics, 62(2), 474–483.CrossRefGoogle Scholar
  6. Bellcross, C., Kolor, K., Goddard, K., Coates, R., Reyes, M., & Khoury, M. (2011). Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. American Journal of Preventive Medicine, 40(1), 61–66. doi: 10.1016/j.amepre.2010.09.027.CrossRefGoogle Scholar
  7. Bensend, T., Veach, P., & Niendorf, K. (2014). What’s the harm? genetic counselor perceptions of adverse effects of genetics service provision by non-genetics professionals. Journal of Genetic Counseling, 23(1), 48–63. doi: 10.1007/s10897-013-9605-3.CrossRefGoogle Scholar
  8. Bowen, M. S., Kolor, K., Dotson, W. D., Ned, R. M., & Khoury, M. J. (2012). Public health action in genomics is now needed beyond newborn screening. Public Health Genomics, 15(6), 327–334. doi: 10.1159/000341889.CrossRefGoogle Scholar
  9. Brierley, K. L., Blouche, E., Cogswell, W., Homer, J. P., Pencarinha, D., Stanislaw, C. L., & Matloff, E. T. (2012). Adverse events in cancer genetic testing: medical, ethical, legal, and financial implications. Cancer Journal (Sudbury, Mass), 18(4), 303–309. doi: 10.1097/PPO.0b013e3182609490.CrossRefGoogle Scholar
  10. Centers for Disease Control and Prevention, Office of Public Health Genomics (2013). Genomic Tests and Family History by Levels of Evidence. Retrieved from http://www.cdc.gov/genomics/gtesting/tier.htm
  11. Chivers Seymour, K., Addington-Hall, J., Lucassen, A., & Foster, C. (2010). What facilitates or impedes family communication following genetic testing for cancer risk? a systematic review and meta-synthesis of primary qualitative research. Journal of Genetic Counseling, 19(4), 330–342. doi: 10.1007/s10897-010-9296-y.CrossRefGoogle Scholar
  12. Cohen, S., Marvin, M., Riley, B., Vig, H., Rousseau, J., & Gustafson, S. (2013). Identification of genetic counseling service delivery models in practice: a report from the NSGC service delivery model task force. Journal of Genetic Counseling, 22(4), 411–421. doi: 10.1007/s10897-013-9588-0.CrossRefGoogle Scholar
  13. Cox, S., Zlot, A., Silvey, K., Elliott, D., Horn, T., Johnson, A., & Leman, R. (2012). Patterns of cancer genetic testing: a randomized survey of Oregon clinicians. Journal of Cancer Epidemiology, 2012294730. doi:10.1155/2012/294730CrossRefGoogle Scholar
  14. Cox, S., George R., Soule J., Parkman, A., Kovak, K., Patil, M., & Shipley, D. (2014). Increasing awareness of hereditary breast and ovarian cancer syndrome (HBOC) among survivors and their providers through the Oregon State Cancer Registry (OSCaR). Poster presented at the 7th biennial Cancer Survivorship Research Conference, Atlanta, GA.Google Scholar
  15. Crotser, C., & Dickerson, S. (2010). Learning about a twist in the road: perspectives of at-risk relatives learning of potential for cancer. Oncology Nursing Forum, 37(6), 723–733. doi: 10.1188/10.ONF. 723-733.CrossRefGoogle Scholar
  16. Dilzell, K., Kingham, K., Ormond, K., & Ladabaum, U. (2014). Evaluating the utilization of educational materials in communicating about Lynch syndrome to at-risk relatives. Familial Cancer, 13(3), 381–389. doi: 10.1007/s10689-014-9720-9.CrossRefGoogle Scholar
  17. DuBois, S., & Kowdley, K. V. (2004). Review article: targeted screening for hereditary haemochromatosis in high-risk groups. Alimentary Pharmacology & Therapeutics, 20(1), 1–14.CrossRefGoogle Scholar
  18. Dugan, R., Wiesner, G., Juengst, E., O’Riordan, M., Matthews, A., & Robin, N. (2003). Duty to warn at-risk relatives for genetic disease: genetic counselors’ clinical experience. American Journal of Medical Genetics Part C Seminars In Medical Genetics, 119C(1), 27–34.CrossRefGoogle Scholar
  19. Engel, N., Gordon, P., Thull, D., Dudley, B., Herstine, J., Jankowitz, R., & Zorn, K. (2012). A multidisciplinary clinic for individualizing management of patients at increased risk for breast and gynecologic cancer. Familial Cancer, 11(3), 419–427. doi: 10.1007/s10689-012-9530-x.CrossRefGoogle Scholar
  20. Fehniger, J., Lin, F., Beattie, M., Joseph, G., & Kaplan, C. (2013). Family communication of BRCA1/2 results and family uptake of BRCA1/2 testing in a diverse population of BRCA1/2 carriers. Journal of Genetic Counseling, 22(5), 603–612. doi: 10.1007/s10897-013-9592-4.CrossRefGoogle Scholar
  21. Forrest, L., Delatycki, M., Curnow, L., Skene, L., & Aitken, M. (2010). Genetic health professionals and the communication of genetic information in families: practice during and after a genetic consultation. American Journal of Medical Genetics Part A, 152A(6), 1458–1466. doi: 10.1002/ajmg.a.33385.Google Scholar
  22. Gaff, C., & Hodgson, J. (2014). A genetic counseling intervention to facilitate family communication about inherited conditions. Journal of Genetic Counseling, 23(5), 814–823. doi: 10.1007/s10897-014-9696-5.CrossRefGoogle Scholar
  23. Genetic Nurse Credentialing Commission (n.d.). Genetic Nursing Credentialing Commission. Retrieved from http://geneticnurse.org/home.html.
  24. Goetzel, R., Ozminkowski, R., Villagra, V., & Duffy, J. (2005). Return on investment in disease management: a review. Healthcare Financing Review, 26(4), 1–19.Google Scholar
  25. Gustafson, S., Pfeiffer, G., & Eng, C. (2011). A large health system’s approach to utilization of the genetic counselor CPT® 96040 code. Genetics in Medicine: Official Journal of the American College Of Medical Genetics, 13(12), 1011–1014. doi: 10.1097/GIM.0b013e3182296344.CrossRefGoogle Scholar
  26. Hampel, H., & de la Chapelle, A. (2011). The search for unaffected individuals with Lynch syndrome: do the ends justify the means? Cancer Prevention Research (Philadelphia, Pa.), 4(1), 1–5. doi: 10.1158/1940-6207.CAPR-10-0345.CrossRefGoogle Scholar
  27. Hardcastle, S. J., Legge, E., Laundy, C. S., Egan, S. J., French, R., Watts, G. F., & Hagger, M. S. (2014). Patients’ perceptions and experiences of familial hypercholesterolemia, cascade genetic screening and treatment. International Journal of Behavioral Medicine. Available from http://link.springer.com/article/10.1007%2Fs12529-014-9402-x#page-1. doi:  10.1007/s12529-014-9402-x.CrossRefGoogle Scholar
  28. Harrison, T., Doyle, D., McGowan, C., Cohen, L., Repass, E., Pfau, R., & Brown, T. (2010). Billing for medical genetics and genetic counseling services: a national survey. Journal of Genetic Counseling, 19(1), 38–43. doi: 10.1007/s10897-009-9249-5.CrossRefGoogle Scholar
  29. Heald, B., Gustafson, S., Mester, J., Arscott, P., Lynch, K., Moline, J., & Eng, C. (2013). A time study of cancer genetic counselors using a genetic counselor-only patient care model versus a traditional combined genetic counselor plus medical geneticist care model. Journal of the National Comprehensive Cancer Network JNCCN, 11(9), 1076–1081.CrossRefGoogle Scholar
  30. Health Insurance Portability and Accountability Act of 1996, H.R. 3103, 104th Congress.Google Scholar
  31. Hodgson, J., Metcalfe, S., Aitken, M., Donath, S., Gaff, C., Winship, I., & …Halliday, J. (2014). Improving family communication after a new genetic diagnosis: a randomised controlled trial of a genetic counselling intervention. BMC Medical Genetics, 1533. doi:10.1186/1471-2350-15-33.Google Scholar
  32. Institute for Healthcare Improvement (n.d.). The IHI Triple Aim. Retrieved January 17, 2014, from http://www.ihi.org/offerings/initiatives/tripleaim/pages/default.aspx.
  33. Invitae (n.d.). BRCA testing is just the beginning (brochure). Retrieved August 22, 2014, from https://www.invitae.com/static/data/Invitae_BRCA_brochure.pdf.
  34. Jasperson, K. (2013). Colorectal cancer: cascade genetic testing in Lynch syndrome: room for improvement. Nature Reviews. Gastroenterology & Hepatology, 10(9), 506–508. doi: 10.1038/nrgastro.2013.122.Google Scholar
  35. Kardashian, A., Fehniger, J., Creasman, J., Cheung, E., & Beattie, M. (2012). A pilot study of the sharing risk information tool (ShaRIT) for families with hereditary breast and ovarian cancer syndrome. Hereditary Cancer in Clinical Practice, 10(1), 4. doi: 10.1186/1897-4287-10-4.CrossRefGoogle Scholar
  36. Kohlmann W., & Gruber S. B. (2004) Lynch Syndrome. In Pagon, R. A., Adam, M. P., Ardinger, H. H., Bird, T. D., Dolan, C. R., Fong, C., & … Stephens, K. (Eds.), GeneReviews. Retrieved from: http://www.ncbi.nlm.nih.gov/books/NBK1211/.
  37. Krawczak, M., Cooper, D., & Schmidtke, J. (2001). Estimating the efficacy and efficiency of cascade genetic screening. American Journal of Human Genetics, 69(2), 361–370.CrossRefGoogle Scholar
  38. Laberge, A., & Burke, W. (2009). Duty to warn at-risk family members of genetic disease. The Virtual Mentor VM, 11(9), 656–660. doi: 10.1001/virtualmentor.2009.11.9.ccas1-0909.CrossRefGoogle Scholar
  39. Lapointe, J., Côté, C., Bouchard, K., Godard, B., Simard, J., & Dorval, M. (2013). Life events may contribute to family communication about cancer risk following BRCA1/2 testing. Journal of Genetic Counseling, 22(2), 249–257. doi: 10.1007/s10897-012-9531-9.CrossRefGoogle Scholar
  40. McPherson, E., Zaleski, C., Benishek, K., McCarty, C., Giampietro, P., Reynolds, K., & Rasmussen, K. (2008). Clinical genetics provider real-time workflow study. Genetics in Medicine: Official Journal of the American College of Medical Genetics, 10(9), 699–706. doi: 10.1097/GIM.0b013e318182206f.CrossRefGoogle Scholar
  41. Menko, F., Aalfs, C., Henneman, L., Stol, Y., Wijdenes, M., Otten, E., & Tibben, A. (2013). Informing family members of individuals with Lynch syndrome: a guideline for clinical geneticists. Familial Cancer, 12(2), 319–324. doi: 10.1007/s10689-013-9636-9.CrossRefGoogle Scholar
  42. Myriad (n.d.). Non-covered services consent form. Retrieved August 22, 2014, from https://www.myriad.com/lib/insurance/NCSF.pdf.
  43. National Cancer Institute (2014a). BRCA1 and BRCA2: Cancer Risk and Genetic Testing. Retrieved from http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA.
  44. National Cancer Institute (2014b). Genetics of Breast and Ovarian Cancer (PDQ®). Retrieved from http://cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional.
  45. National Society of Genetic Counselors (2011). Genetic Counselors in Healthcare Reform. Retrieved from http://nsgc.org/p/bl/et/blogid=47&blogaid=26.
  46. National Society of Genetic Counselors (2014). States issuing licenses for genetic counselors. Retrieved from http://nsgc.org/p/cm/ld/fid=19.
  47. National Society of Genetic Counselors (n.d.). Students and Prospective Genetic Counselors. Retrieved from http://nsgc.org/p/cm/ld/fid=43.
  48. Nordestgaard, B., Chapman, M., Humphries, S., Ginsberg, H., Masana, L., Descamps, O., & Tybjærg-Hansen, A. (2013). Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. European Heart Journal, 34(45), 3478–90a. doi: 10.1093/eurheartj/eht273.CrossRefGoogle Scholar
  49. Offit, K., Groeger, E., Turner, S., Wadsworth, E., & Weiser, M. (2004). The “duty to warn” a patient’s family members about hereditary disease risks. JAMA, the Journal of the American Medical Association, 292(12), 1469–1473.CrossRefGoogle Scholar
  50. Oregon Health Policy Board. (n.d.). Coordinated Care Organizations. Retrieved January 1, 2014, from http://www.oregon.gov/oha/OHPB/Pages/health-reform/ccos.aspx
  51. Oregon Health Authority, Oregon Genetics Program. (2011a). [Behavioral Risk Factor Surveillance System Survey Data]. Unpublished raw data.Google Scholar
  52. Oregon Health Authority, Oregon Genetics Program. (2011b) Health Insurance Coverage of Genetic Services Programs in Oregon. Retrieved from https://public.health.oregon.gov/DiseasesConditions/GeneticConditions/Documents/ReportSurveyPSU2011.pdf.
  53. Oregon Health Authority, Oregon Genetics Program (2011c). Healthcare Provider Survey Findings. Retrieved from http://public.health.oregon.gov/DiseasesConditions/GeneticConditions/Documents/HCPSummary.pdf.
  54. Oregon Health Authority, Oregon Genetics Program. (2013). [BRCA Testing Surveillance Study]. Unpublished raw data.Google Scholar
  55. Oregon Health Authority, Oregon Genetics Program. (2014) Third Party Payer Hereditary Breast and Ovarian Cancer (HBOC) Syndrome Counseling and Testing. Report in preparation.Google Scholar
  56. Patient Protection and Affordable Care Act of 2010, H.R. 3590, 111th Congress.Google Scholar
  57. Petrucelli N, Daly MB, Feldman GL. (1998) BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. In Pagon, R. A., Adam, M. P., Ardinger, H. H., Bird, T. D., Dolan, C. R., Fong, C., & … Stephens, K. (Eds.), GeneReviews. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK1247/.
  58. Radford, C., Prince, A., Lewis, K., & Pal, T. (2013). Factors which impact the delivery of genetic risk assessment services focused on inherited cancer genomics: expanding the role and reach of certified genetics professionals. Journal of Genetic Counseling. doi: 10.1007/s10897-013-9668-1.CrossRefGoogle Scholar
  59. Sharaf, R., Myer, P., Stave, C., Diamond, L., & Ladabaum, U. (2013). Uptake of genetic testing by relatives of Lynch syndrome probands: a systematic review. Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association, 11(9), 1093–1100. doi: 10.1016/j.cgh.2013.04.044.CrossRefGoogle Scholar
  60. Tarasoff v Regents of the University of California, 17 Cal 3d 425, 551 P2d 334, 131 Cal Rptr 14 (Cal 1976).Google Scholar
  61. Trivers, K., Baldwin, L., Miller, J., Matthews, B., Andrilla, C., Lishner, D., & Goff, B. (2011). Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study. Cancer, 117(23), 5334–5343. doi: 10.1002/cncr.26166.CrossRefGoogle Scholar
  62. U.S. Census Bureau. (2014). State and County Quick Facts-USA. Retreived from http://quickfacts.census.gov/qfd/states/00000.html.
  63. U.S. Department of Health and Human Services. (2012). Preventive Services Covered Under the Affordable Care Act. Retrieved from http://www.hhs.gov/healthcare/facts/factsheets/2010/07/preventive-services-list.html
  64. U.S. Preventive Services Taskforce. (2005). Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Annals of Internal Medicine, 143(5), 355–361.CrossRefGoogle Scholar
  65. U.S. Preventive Services Taskforce (2013). BRCA-related cancer: Risk assessment, genetic counseling, and genetic testing. Retrieved from http://www.uspreventiveservicestaskforce.org/Page/Topic/recommendation-summary/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing
  66. University of California at San Francisco. (n.d.). Kintalk. Retrieved August 22, 2014, from http://kintalk.org/
  67. Vos, J., Menko, F., Jansen, A., van Asperen, C., Stiggelbout, A., & Tibben, A. (2011). A whisper-game perspective on the family communication of DNA-test results: a retrospective study on the communication process of BRCA1/2-test results between proband and relatives. Familial Cancer, 10(1), 87–96. doi: 10.1007/s10689-010-9385-y.CrossRefGoogle Scholar
  68. Wham, D., Vu, T., Chan-Smutko, G., Kobelka, C., Urbauer, D., & Heald, B. (2010). Assessment of clinical practices among cancer genetic counselors. Familial Cancer, 9(3), 459–468. doi: 10.1007/s10689-010-9326-9.CrossRefGoogle Scholar
  69. Wood, M., Stockdale, A., & Flynn, B. (2008). Interviews with primary care physicians regarding taking and interpreting the cancer family history. Family Practice, 25(5), 334–340. doi: 10.1093/fampra/cmn053.CrossRefGoogle Scholar
  70. World Health Organization. (n.d.). Public Health. Retrieved from http://www.who.int/trade/glossary/story076/en/.
  71. Youngblom E. & Knowles J. W. (2014) Familial Hypercholesterolemia. In Pagon, R. A., Adam, M. P., Ardinger, H. H., Bird, T. D., Dolan, C. R., Fong, C., & … Stephens, K. (Eds.), GeneReviews. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK174884/

Copyright information

© National Society of Genetic Counselors, Inc. 2015

Authors and Affiliations

  1. 1.Oregon Genetics ProgramOregon Health AuthorityPortlandUSA
  2. 2.Department of Molecular and Medical GeneticsOregon Health & Sciences UniversityPortlandUSA

Personalised recommendations